Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recarbrio for KPC-producing CRE Infections
NCT04785924Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imipenem + cilastatin + relebactam in Enterobacteriaceae infection, sponsored by Wake Forest University Health Sciences. Primary endpoints: Clinical success at 30 days and Clinical success by site of infection at 30 days. Planned start Jun 2021; status: withdrawn.
02
Drugs
imipenem + cilastatin + relebactam
03
Conditions
Enterobacteriaceae infection
Beyond the preview
Go deeper on NCT04785924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785924.